Sawai Chalks Up More Than A Dozen Launches
Follows Approvals From Japan's MHLW Earlier This Year
Sawai has followed-up on a raft of approvals announced earlier this year with launch plans, including for the first generics of Daiichi Sankyo’s Memary (memantine hydrochloride) Alzheimer’s disease treatment in three presentations.
You may also be interested in...
Upsher-Smith Laboratories, the US arm of Japan’s Sawai Pharmaceutical, has another challenging project in the pipeline with an agreement to develop and market a follow-on version of Mallinckrodt’s Acthar Gel (corticotropin). The Japanese firm revealed Upsher-Smith’s latest finances as it revealed first-quarter financial results.
Sawai and Nichi-Iko are in the crosshairs of Chugai after the originator filed a lawsuit in Japan claiming patent infringement over the pair’s generic eldecalcitol versions of its Edirol brand.
Sales growth through new product launches and increasing the value of its current portfolio will allow Sawai to increase sales by around a tenth this year, the Japanese firm has forecasted, as it also revealed full-year financials for the 12 months ended 31 March 2020.